Xi Niu Cai Jing·2025-06-11 05:01Group 1 - Fangzheng Technology plans to raise no more than 1.98 billion yuan through a private placement to fund an AI and high-density interconnect circuit board project [1] - The issuance will not exceed 1.251 billion shares, with the controlling shareholder participating in the subscription [1] - Lianhuan Pharmaceutical received an administrative penalty totaling 61.0382 million yuan for violating antitrust laws, which will reduce its 2025 net profit by the same amount [2][3] Group 2 - *ST Jingang signed a restructuring investment agreement with Ouhao Group, which will facilitate the company's restructuring process [4] - The subsidiary Hong Kong Jingang signed a sales contract for 194MW HJT solar cells, expected to account for over 50% of the company's audited revenue for 2024 [4] - Honghe Technology will change to having no actual controller after a share transfer agreement, with its stock resuming trading [5] Group 3 - Huadong Medicine's subsidiary received approval for a clinical trial of 0.3% Roflumilast foam for seborrheic dermatitis patients [6] - Guangting Information plans to acquire 100% of Chengdu Kaimate Technology for 360 million yuan, using part of the funds from oversubscription [6][7] - Jiafa Education's shareholder plans to reduce holdings by up to 3% of the company's shares [8] Group 4 - Caida Securities' shareholder plans to reduce holdings by up to 3% of the company's shares [9] - Kute Intelligent announced plans to issue H-shares and list on the Hong Kong Stock Exchange to advance its global strategy [10] - Qianzhai Optical's shareholders plan to reduce holdings by up to 3% of the company's shares [20] Group 5 - *ST Weihai plans to publicly transfer 90.31% of its subsidiary Shanghai Qinnian's shares to focus on its main business [23] - Jiangnan Chemical intends to acquire 51% of Ebian Guochang for approximately 170 million yuan, aiming to comply with national industry restructuring policies [24][25]